Aclarion (NASDAQ:ACON) Stock Rating Upgraded by Wall Street Zen

Aclarion (NASDAQ:ACON) was upgraded by Wall Street Zen to a “hold” rating in a research note issued to investors on Saturday.

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Aclarion in a research report on Wednesday, October 8th. One analyst has rated the stock with a Sell rating, According to MarketBeat, the company presently has an average rating of “Sell”.

Aclarion Stock Performance

Shares of ACON stock opened at $5.39 on Friday. Aclarion has a fifty-two week low of $5.02 and a fifty-two week high of $3,499.51. The company has a market cap of $3.61 million, a PE ratio of -0.36 and a beta of 1.43. The stock’s fifty day moving average price is $6.68 and its two-hundred day moving average price is $7.24.

Aclarion (NASDAQ:ACON) last announced its quarterly earnings results on Wednesday, November 12th. The company reported ($2.93) earnings per share (EPS) for the quarter, missing the consensus estimate of ($2.64) by ($0.29). The company had revenue of $0.02 million for the quarter, compared to analyst estimates of $0.02 million. Aclarion had a negative return on equity of 67.53% and a negative net margin of 10,908.50%. On average, equities analysts predict that Aclarion will post -263.33 EPS for the current fiscal year.

Aclarion Company Profile

Aclarion, Inc, a healthcare technology company, leverages for Magnetic Resonance Spectroscopy (MRS) in the United States. It develops NOCISCAN Post-Processor suite of software applications comprising NOCICALC that receives the raw un-processed NOCISCAN MRS exam data and post-processes that raw data into final spectra and performs various degenerative pain biomarker; and NOCIGRAM, a clinical decision support software. The company was formerly known as Nocimed, Inc and changed its name to Aclarion, Inc in December 2021.